Vyvgart

imaavy-for-generalized-myasthenia-gravis

May 16, 2025

J&J Enters gMG Arena with IMAAVY Approval, Challenging AstraZeneca, Argenx, and UCB

fcrn-inhibitors-in-20-indications

Jul 15, 2024

FcRn Inhibitors Being The Fastest Growing Class, Plans To Get Explored In 20+ Indications

fcrn-inhibitors-for-autoimmune-disorders

May 06, 2024

FcRn Inhibitors for Autoimmune Disorders: A Promising Therapeutic Approach

drugs-launched-in-second-half-2021

Jan 05, 2022

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper